Nateglinide
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Insulin Resistance
Conditions
Insulin Resistance, Impaired Fasting Glucose
Trial Timeline
Jun 1, 2003 → Mar 1, 2006
NCT ID
NCT00259168About Nateglinide
Nateglinide is a approved stage product being developed by Novartis for Insulin Resistance. The current trial status is completed. This product is registered under clinical trial identifier NCT00259168. Target conditions include Insulin Resistance, Impaired Fasting Glucose.
What happened to similar drugs?
6 of 20 similar drugs in Insulin Resistance were approved
Approved (6) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00402909 | Approved | Completed |
| NCT00259168 | Approved | Completed |
| NCT00238472 | Approved | Completed |
Competing Products
20 competing products in Insulin Resistance